Karuna Therapeutics Statistics Share Statistics Karuna Therapeutics has 38.2M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 38.2M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) n/a Shares Floating 36.27M Failed to Deliver (FTD) Shares 3 FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 1.92M, so 0% of the outstanding
shares have been sold short.
Short Interest 1.92M Short % of Shares Out n/a Short % of Float n/a Short Ratio (days to cover) 2.65
Valuation Ratios The PE ratio is -26.97 and the forward
PE ratio is 659.66.
Karuna Therapeutics's PEG ratio is
-0.79.
PE Ratio -26.97 Forward PE 659.66 PS Ratio 17886.71 Forward PS 17.7 PB Ratio 9.33 P/FCF Ratio -30.09 PEG Ratio -0.79
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Karuna Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 19.31,
with a Debt / Equity ratio of 0.01.
Current Ratio 19.31 Quick Ratio 18.82 Debt / Equity 0.01 Debt / EBITDA -0.03 Debt / FCF -0.04 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $1.93K Profits Per Employee $-1.28M Employee Count 339 Asset Turnover 0 Inventory Turnover 0.05
Taxes Income Tax 670K Effective Tax Rate -0.15%
Stock Price Statistics The stock price has increased by 0% in the
last 52 weeks. The beta is 1.15, so Karuna Therapeutics's
price volatility has been higher than the market average.
Beta 1.15 52-Week Price Change n/a 50-Day Moving Average 317.67 200-Day Moving Average 228.83 Relative Strength Index (RSI) 75.4 Average Volume (20 Days) 971,825
Income Statement In the last 12 months, Karuna Therapeutics had revenue of 654K
and earned -433.68M
in profits. Earnings per share was -11.73.
Revenue 654K Gross Profit -1.05M Operating Income -494.78M Net Income -433.68M EBITDA -493.08M EBIT -494.78M Earnings Per Share (EPS) -11.73
Full Income Statement Balance Sheet The company has 185.82M in cash and 16.69M in
debt, giving a net cash position of 169.13M.
Cash & Cash Equivalents 185.82M Total Debt 16.69M Net Cash 169.13M Retained Earnings -997.89M Total Assets 1.34B Working Capital 1.25B
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -385.82M
and capital expenditures -2.92M, giving a free cash flow of -388.74M.
Operating Cash Flow -385.82M Capital Expenditures -2.92M Free Cash Flow -388.74M FCF Per Share -10.52
Full Cash Flow Statement Margins Gross margin is -160.09%, with operating and profit margins of -75653.98% and -66311.93%.
Gross Margin -160.09% Operating Margin -75653.98% Pretax Margin -66209.48% Profit Margin -66311.93% EBITDA Margin -75393.88% EBIT Margin -75653.98% FCF Margin -59439.76%
